Skip to main content

Advertisement

Log in

Racial Differences in Cancer Specialist Consultation, Treatment, and Outcomes for Locoregional Pancreatic Adenocarcinoma

  • Healthcare Policy and Outcomes
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Blacks have a higher incidence of pancreatic adenocarcinoma and worse outcomes compared to whites. Identifying barriers in pancreatic cancer care may explain survival differences and provide areas for intervention.

Methods

Pancreatic adenocarcinoma patients were identified in the Surveillance, Epidemiology, and End Results Registry (1991–2002). Treatment and outcome data were obtained from the linked Surveillance, Epidemiology, and End Results Registry–Medicare databases. Logistic regression was used to assess race as a predictor of specialist consultation/receipt of therapy. Kaplan–Meier survival curves were compared. Cox proportional hazard analyses were performed to estimate survival after adjustment for patient and treatment characteristics.

Results

A total of 13,230 white patients (90%) and 1478 black patients (10%) were identified. Clinical/pathologic factors were compared by race. When we compared whites and blacks by univariate analyses, blacks had lower rates of specialist consultation (P < .01), chemotherapy (P < .01), and resection (P < .01). On multivariate analyses predicting consultation with a cancer specialist, black race negatively predicted consultation with a medical oncologist (adjusted odds ratio [AOR] .74, P < .01), radiation oncologist (AOR .75, P < .01), and surgeon (AOR .71, P < .01). For predicting receipt of therapy after consultation, blacks were less likely to undergo chemotherapy (AOR .59, P < .01) and resection (AOR .79, P = .05). Blacks had worse overall survival on Kaplan–Meier survival curves (log rank, P < .0001). On Cox proportional hazard modeling evaluating survival, black race was no longer independently associated with worse survival after adjustment for resection and adjuvant therapy (hazard ratio, 1.08; 95% confidence interval, .99–1.19).

Conclusions

Racial disparities exist in pancreatic cancer specialist consultation and subsequent therapy use. Because receipt of care is fundamental to reducing outcome discrepancies, these barriers serve as discrete intervention points to ensure all locoregional pancreatic adenocarcinoma patients receive appropriate specialist referral and subsequent therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

    Article  PubMed  Google Scholar 

  2. National Cancer Institute. SEER cancer statistics review 2005: age-adjusted SEER incidence and US death rates and 5-year relative survival rates. http://seer.cancer.gov/csr/1975_2005/. Accessed 4 Aug 2009.

  3. Horner M, Ries LAG, Krapcho M, et al. SEER cancer statistics review, 1975–2006. Bethesda, MD: National Cancer Institute; 2009. http://seer.cancer.gov/csr/1975_2006. Accessed 4 Aug 2009.

  4. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766–73.

    Article  PubMed  Google Scholar 

  5. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455–65.

    CAS  PubMed  Google Scholar 

  6. Bertagnolli MM. Surgical prevention of cancer. J Clin Oncol. 2005;23:324–32.

    Article  PubMed  Google Scholar 

  7. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.

    CAS  PubMed  Google Scholar 

  8. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.

    Article  CAS  PubMed  Google Scholar 

  9. Chua YJ, Cunningham D. Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol. 2005;23:4532–7.

    Article  CAS  PubMed  Google Scholar 

  10. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.

    Article  CAS  PubMed  Google Scholar 

  11. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334–57.

    PubMed  Google Scholar 

  12. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–300.

    Article  PubMed  Google Scholar 

  13. O’Malley CD, Le GM, Glaser SL, Shema SJ, West DW. Socioeconomic status and breast carcinoma survival in four racial/ethnic groups: a population-based study. Cancer. 2003;97:1303–11.

    Article  PubMed  Google Scholar 

  14. Steyerberg EW, Neville B, Weeks JC, Earle CC. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2007;25:2389–96.

    Article  PubMed  Google Scholar 

  15. Steyerberg EW, Earle CC, Neville BA, Weeks JC. Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2005;23:510–7.

    Article  PubMed  Google Scholar 

  16. McCann J, Artinian V, Duhaime L, et al. Evaluation of the causes for racial disparity in surgical treatment of early stage lung cancer. Chest. 2005;128:3440–6.

    Article  PubMed  Google Scholar 

  17. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198–205.

    Article  CAS  PubMed  Google Scholar 

  18. Rogers SO, Ray WA, Smalley WE. A population-based study of survival among elderly persons diagnosed with colorectal cancer: does race matter if all are insured? (United States). Cancer Causes Control. 2004;15:193–9.

    Article  PubMed  Google Scholar 

  19. Murphy MM, Simons JP, Hill J, Tseng JF. Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer (2009). [Epub ahead of print].

  20. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002;20:1786–92.

    Article  PubMed  Google Scholar 

  21. Tseng JF, Kronowitz SJ, Sun CC, et al. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer 2004;101:1514–23.

    Article  PubMed  Google Scholar 

  22. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40 Suppl 8:IV-3–18.

    Google Scholar 

  23. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732–48.

    Article  CAS  PubMed  Google Scholar 

  24. World Health Organization. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.

  25. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg 2007;246:173–80.

    Article  PubMed  Google Scholar 

  26. Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev. 2007;16:546–52.

    Article  PubMed  Google Scholar 

  27. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40 Suppl 8:IV-19–25.

    Google Scholar 

  28. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002;40 Suppl 8:IV-26–35.

    Google Scholar 

  29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

    Article  CAS  PubMed  Google Scholar 

  30. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.

    Article  CAS  PubMed  Google Scholar 

  31. Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40 Suppl 8:IV-49–54.

    Google Scholar 

  32. International classification of diseases. 9th rev., clinical modification. Salt Lake City: Medicode Publications; 2001.

  33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn. 1958;185:1457–81.

    Google Scholar 

  34. Eloubeidi MA, Desmond RA, Wilcox CM, et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg. 2006;192:322–9.

    Article  PubMed  Google Scholar 

  35. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21:3409–14.

    Article  PubMed  Google Scholar 

  36. Davila JA, Chiao EY, Hasche JC, et al. Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. Pancreas 2009;38:e18–25.

    Article  CAS  PubMed  Google Scholar 

  37. Sewitch MJ, Fournier C, Dawes M, et al. Do physician recommendations for colorectal cancer screening differ by patient age? Can J Gastroenterol. 2007;21:435–8.

    PubMed  Google Scholar 

  38. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. JAMA. 1986;255:3385–90.

    Article  CAS  PubMed  Google Scholar 

  39. Rathore SS, Krumholz HM. Differences, disparities, and biases: clarifying racial variations in health care use. Ann Intern Med. 2004;141:635–8.

    PubMed  Google Scholar 

  40. Dein S. Explanatory models of and attitudes towards cancer in different cultures. Lancet Oncol. 2004;5:119–24.

    Google Scholar 

  41. Whittle J, Conigliaro J, Good CB, Joswiak M. Do patient preferences contribute to racial differences in cardiovascular procedure use? J Gen Intern Med. 1997;12:267–73.

    Article  CAS  PubMed  Google Scholar 

  42. Oddone EZ, Horner RD, Diers T, et al. Understanding racial variation in the use of carotid endarterectomy: the role of aversion to surgery. J Natl Med Assoc. 1998;90:25–33.

    CAS  PubMed  Google Scholar 

  43. Lannon C, Brack V, Stuart J, et al. What mothers say about why poor children fall behind on immunizations. A summary of focus groups in North Carolina. Arch Pediatr Adolesc Med. 1995;149:1070–5.

    CAS  PubMed  Google Scholar 

  44. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. N Engl J Med. 2004;351:575–84.

    Article  CAS  PubMed  Google Scholar 

  45. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329:326–31.

    Article  CAS  PubMed  Google Scholar 

  46. Perez-Stable EJ, Sabogal F, Otero-Sabogal R, Hiatt RA, McPhee SJ. Misconceptions about cancer among Latinos and Anglos. JAMA. 1992;268:3219–23.

    Article  CAS  PubMed  Google Scholar 

  47. Fox SA, Stein JA. The effect of physician-patient communication on mammography utilization by different ethnic groups. Med Care. 1991;29:1065–82.

    Article  CAS  PubMed  Google Scholar 

  48. Womeodu RJ, Bailey JE. Barriers to cancer screening. Med Clin North Am. 1996;80:115–33.

    Article  CAS  PubMed  Google Scholar 

  49. Ayanian JZ, Cleary PD, Keogh JH, et al. Physicians’ beliefs about racial differences in referral for renal transplantation. Am J Kidney Dis. 2004;43:350–7.

    Article  PubMed  Google Scholar 

  50. Ibrahim SA, Whittle J, Bean-Mayberry B, et al. Racial/ethnic variations in physician recommendations for cardiac revascularization. Am J Public Health. 2003;93:1689–93.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

We thank Bridget A. Neville, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, for her statistical expertise. This work was supported by the Evans-Allen-Griffin Fellowship (M.M.M.), the Pancreatic Cancer Alliance (J.P.S. and J.F.T.), the American Surgical Association Foundation, the Howard Hughes Early Career Award, and an American Cancer Society Institutional Research Grant (all to J.F.T.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer F. Tseng MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murphy, M.M., Simons, J.P., Ng, S.C. et al. Racial Differences in Cancer Specialist Consultation, Treatment, and Outcomes for Locoregional Pancreatic Adenocarcinoma. Ann Surg Oncol 16, 2968–2977 (2009). https://doi.org/10.1245/s10434-009-0656-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0656-5

Keywords

Navigation